Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Assets (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Current Assets data on record, last reported at $613.9 million in Q3 2025.

  • For Q3 2025, Current Assets rose 38.32% year-over-year to $613.9 million; the TTM value through Sep 2025 reached $613.9 million, up 38.32%, while the annual FY2024 figure was $482.3 million, 10.29% down from the prior year.
  • Current Assets reached $613.9 million in Q3 2025 per COLL's latest filing, up from $549.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $613.9 million in Q3 2025 and bottomed at $296.3 million in Q1 2021.
  • Average Current Assets over 5 years is $456.2 million, with a median of $482.3 million recorded in 2024.
  • Peak YoY movement for Current Assets: skyrocketed 38.57% in 2021, then dropped 17.37% in 2024.
  • A 5-year view of Current Assets shows it stood at $315.5 million in 2021, then skyrocketed by 33.1% to $420.0 million in 2022, then grew by 28.0% to $537.6 million in 2023, then dropped by 10.29% to $482.3 million in 2024, then rose by 27.29% to $613.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $613.9 million in Q3 2025, $549.2 million in Q2 2025, and $527.6 million in Q1 2025.